Repro-Med Systems (OTCMKTS:REPR) versus Pro-Dex (OTCMKTS:PDEX) Financial Analysis

Repro-Med Systems (OTCMKTS:REPR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Repro-Med Systems and Pro-Dex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repro-Med Systems 0.17% 7.63% 6.31%
Pro-Dex 15.32% 24.02% 16.60%

Analyst Ratings

This is a summary of recent recommendations for Repro-Med Systems and Pro-Dex, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repro-Med Systems 0 0 1 0 3.00
Pro-Dex 0 0 1 0 3.00

Pro-Dex has a consensus price target of $20.00, suggesting a potential upside of 26.58%. Given Pro-Dex’s higher probable upside, analysts plainly believe Pro-Dex is more favorable than Repro-Med Systems.

Earnings & Valuation

This table compares Repro-Med Systems and Pro-Dex’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Repro-Med Systems $17.35 million 8.76 $910,000.00 N/A N/A
Pro-Dex $27.17 million 2.32 $4.15 million N/A N/A

Pro-Dex has higher revenue and earnings than Repro-Med Systems.

Institutional & Insider Ownership

17.3% of Repro-Med Systems shares are held by institutional investors. Comparatively, 15.8% of Pro-Dex shares are held by institutional investors. 40.0% of Repro-Med Systems shares are held by insiders. Comparatively, 41.7% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Repro-Med Systems has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Summary

Pro-Dex beats Repro-Med Systems on 8 of the 10 factors compared between the two stocks.

About Repro-Med Systems

Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.

About Pro-Dex

Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Receive News & Ratings for Repro-Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro-Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.